Inhibikase Therapeutics (IKT) EBT (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly EBT came in at -$17.8 million in Q1 2026, down 22.21% year-on-year from -$22.9 million in Q1 2025, and up 16.92% on a QoQ basis from -$21.5 million in Q4 2025.
Inhibikase Therapeutics (IKT) EBT (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of EBT data on file, last reported at -$17.8 million in Q1 2026.
- On a quarterly basis, EBT fell 22.21% year-over-year to -$17.8 million in Q1 2026; TTM through Mar 2026 was -$63.0 million, a 62.47% decrease from a year earlier, with the FY2025 full-year figure at -$83.6 million, down 40.11% from the prior year.
- EBT for Q1 2026 stood at -$17.8 million, up from -$21.5 million in the prior quarter.
- Over the last five years, EBT for IKT reached as high as -$4.3 million in Q4 2022 and fell as low as -$21.5 million in Q4 2025.
- Historically, EBT has averaged -$8.5 million across 5 years, with a median of -$5.2 million in 2024.
- Across the five-year window, EBT grew 16.05% in 2024 and tumbled 204.12% in 2025, its largest moves.
- Year by year, EBT stood at -$4.3 million in 2022, then retreated by 1.58% to -$4.4 million in 2023, then slumped by 193.6% to -$12.9 million in 2024, then tumbled by 66.11% to -$21.5 million in 2025, then advanced by 16.92% to -$17.8 million in 2026.
- Per Business Quant data, the three most recent EBT figures were -$17.8 million in Q1 2026, -$21.5 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | -17.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -21.48 Mn |
| Sep 30, 2025 | -12.77 Mn |
| Jun 30, 2025 | -10.87 Mn |
| Mar 31, 2025 | -14.60 Mn |
| Dec 31, 2024 | -12.93 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Jun 30, 2024 | -5.24 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Dec 31, 2023 | -4.40 Mn |
| Sep 30, 2023 | -4.80 Mn |
| Jun 30, 2023 | -6.24 Mn |
| Mar 31, 2023 | -4.76 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -4.56 Mn |
| Jun 30, 2022 | -4.64 Mn |
| Mar 31, 2022 | -4.64 Mn |
| Dec 31, 2021 | -5.02 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | -2.64 Mn |